Articles related to BUSINESS & POLICY

This physician sounds the alarm on CDC’s ill-founded mandates for mandatory masking, citing the recent Cochrane Review.

It may not come as a surprise that there are so many doctors running for politics given that healthcare is a major legislative priority. According to the Patients Action Network of the American Medical Association, 19 doctors are currently serving in the 118th Congress. The task ahead for these 19 congressional representatives will be challenging. The AMA is concentrated on stopping Medicare payment cuts and implementing prior authorization reform among the myriad healthcare concerns facing the nation.

Innovative and creative Risky Business events emphasize risk management, patient safety, and safety awareness. To enable all of their colleagues to work in a safer environment, they continuously “raise the bar” by exchanging safety ideas and experiences across industries. The integration of experiences from speakers representing a wide range of non-healthcare businesses into a coherent narrative and actionable results is a crucial component of Risky Business. In this two-hour video webinar taking place on Thursday, January 12 from 10:00 AM to noon , the panelists will talk about a wide range of topics, including systemic problems, workforce implications, community needs, and what industry experts are doing to address the situation. To address challenges of capacity and resource strain, they will examine cutting-edge digital technology and government and healthcare system collaboration.

Not surprisingly, given the rate at which new FDA approvals are granted, the majority of clinicians prescribed a newly FDA-approved drug in the previous year, with 20% prescribing at least ten new drugs, according to OBRs Oncology Drug Report 2022. The latter metric demonstrates how quickly the world of cancer care is evolving, which has a number of important implications for oncology practice.

According to a survey conducted by the Association for Clinical Oncology, the majority of respondents (96%) said prior authorization has led to delays in cancer treatment, with 80% claiming prior authorization has enabled disease progression, and 36% of them saying prior authorization has led to patient deaths. 300 ASCO members who work in academic or university (29%) settings, private practice (34%), or community or hospital-based health network/systems (35%), completed the survey.

A video conversation between a senior advisor at ADVI, a physician from Texas Oncology, and the division director of practice health for ASCO discuss the main provisions of the Inflation Reduction Act (IRA) and its implications for oncologists and oncology practices. The panel discusses why practices may have to bear a larger share of the cost of drugs and be ready for utilization cuts by focusing on two important aspects of the IRA: the $2,000 cap on patients’ out-of-pocket expenses and Medicare price negotiation. All three concur that if the act isn’t changed, it might slow down the development of medicines for some indications.